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Abstract
Aim—The aim of this study was to
determine the (time trends in) incidence
and survival of hereditary (familial and
sporadic) and non-hereditary retinoblast-
oma for male and female patients born in
the Netherlands between 1862 and 1995.
Method—The national retinoblastoma
register was updated and now consists of
955 patients. The missing dates of death
were obtained from the municipal regis-
ters and the Central Bureau of Genealogy
in The Hague. Mortality was compared
with the Dutch vital statistics.
Results—From 1862 to 1995 no significant
diVerences in incidence for retinoblast-
oma were found in the hereditary sub-
groups. Further, no significant differences
between males and females were found,
both overall and in the hereditary sub-
groups. The average incidence of retino-
blastoma increased untill 1944, probably
due to incompleteness of the register, and
stabilised after 1945 (1 per 17 000 live
births). From 1900 to 1995 the standard-
ised mortality ratio increased for heredi-
tary retinoblastoma patients from 2.9 to
9.0 and decreased for non-hereditary reti-
noblastoma patients from 1.9 to 1.0.
Conclusion—Although survival for retino-
blastoma was significantly better after
1945 than before, in comparison with the
Dutch population the mortality between
1900 and 1990 increased for the hereditary
and decreased for the non-hereditary
retinoblastoma patients.
(Br J Ophthalmol 1997;81:559–562)
Retinoblastoma is a rare paediatric eye tumour
which occurs in a hereditary and a non-
hereditary form. All bilateral (familial or
sporadic) cases and the familial unilateral cases
can be considered to be hereditary (30%–40%
of the cases).1 In familial cases the patient
inherits the retinoblastoma mutation from a
carrier parent and in sporadic bilateral cases
from a healthy parent in whom a new germinal
mutation has occurred.
The incidence of retinoblastoma reported in
the literature ranges from 1:10 000 in South
Africa to 1:34 000 in the Netherlands (Table
1).1–21 These extreme values come from hospi-
tal populations and are based on very crude
estimations and are therefore probably
inaccurate.1 During the past years it has often
been discussed whether there has been any
change in the incidence of this malignant
disease.22 23 The survival rate of retinoblastoma
improved in the last century,24 mostly because
of Wardrop’s recommendation to enucleate a
retinoblastoma eye.25 As a consequence, he-
reditary retinoblastoma patients were able to
have oVspring and this presumably led to a
gradual increase in the incidence of hereditary
retinoblastoma in the population.
Furthermore, there is still a discussion in the
literature regarding the sex predominance of
retinoblastoma patients. Pendergrass and
Davis7 found no diVerence in the incidence of
retinoblastoma between males and females.
Naumova and Sapienza26 found a significant
overrepresentation of males among bilateral
sporadic cases.
Neel27 and Vogel1 discussed a possible viral
aetiology of retinoblastoma. A seasonal varia-
tion in births of children with non-hereditary
retinoblastoma would suggest that the disease
is possibly influenced by certain environmental
agents such as viral infection.
The National Retinoblastoma Register of
the Netherlands oVers the unique opportunity
to analyse the above mentioned controversies
in the literature. Therefore, the purposes of this
study were to determine for hereditary (spo-
radic and familial) and non-hereditary retino-
blastoma patients: (1) the (time trends in) inci-
dence, (2) the diVerence in incidence between
males and females, (3) the diVerence in
incidence between diVerent months, (4) time
trends in survival, (5) the diVerence in survival
between male and female patients.
Methods
The National Retinoblastoma Register of the
Netherlands28 29 was used in the updated
version.30 It can be regarded as virtually
complete for patients born from 1945 to date.17
We gathered the dates of birth and death of the
955 registered Dutch retinoblastoma patients
born from 1862 to 1995. If possible, missing
dates of death of patients were obtained with
the help of the municipal registers and the
Central Bureau of Genealogy in The Hague.
Retinoblastoma was regarded to be heredi-
tary if at least one of the following criteria was
met: bilateral retinoblastoma, family history for
retinoblastoma (then the parent would be car-
rier of the defect in the retinoblastoma gene),
or a defect in the retinoblastoma gene was
found in chromosomal/DNA analysis of the
patient. Sporadic hereditary retinoblastoma
patients are the first cases known in a family.
Some sporadic unilateral retinoblastoma pa-
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tients might be classified incorrectly as non-
hereditary, since approximately 10% of the
hereditary retinoblastoma patients are aVected
unilaterally.1
STATISTICAL ANALYSES
The total annual number of live births by sex in
the Netherlands is available until 1994.31 The
cumulative incidences of the diVerent retino-
blastoma subgroups (sporadic hereditary, fa-
milial hereditary, and non-hereditary) were
calculated in 5 year birth cohorts. The number
of liveborn retinoblastoma patients was divided
by the number of live births in the Netherlands
in the same period (irrespective of the moment
of diagnosis). Linear regression analyses were
performed to detect a significant trend in inci-
dence for the diVerent retinoblastoma groups
from 1862 to 1995.
DiVerence in incidence between sexes was
investigated by testing the percentage of males
in the retinoblastoma group against percent-
ages of males and females in the same birth
cohort in the Dutch population, using the
binominal distribution. Sex diVerences be-
tween the retinoblastoma subgroups were
compared with the ÷2 test for contingency
tables.
DiVerences in incidence between months
were investigated for each retinoblastoma sub-
group, using a multinominal distribution, with
the (relative) monthly birth frequencies of the
Dutch population as variables.
The age at diagnosis was not always available
for the patients born before 1945. Therefore,
the survival curves are based on age since birth
instead of in years after diagnosis. Survival was
described with Kaplan–Meier curves, using the
Mantel–Cox (log rank) test to determine diVe-
rences in survival curves among the groups of
interest.
The standardised mortality ratio (SMR) for
the diVerent retinoblastoma groups was
calculated32 in 10 year mortality groups. An
SMR of 1.25 for example means 25% ‘extra
mortality’ in the retinoblastoma patients in
comparison with the Dutch population.33 The
Dutch mortality rates in age groups per calen-
dar year of death were available from 1900 to
date.34 Confidence intervals (95% CI) were
calculated using the logarithm of the SMR.32 In
order to detect a trend in the SMR from 1900
to 1995 regression analyses on the logarithm of
the SMR were done. This project was ap-
proved by the medical ethics committee of the
Free University Hospital, Amsterdam, the
Netherlands.
Results
HEREDITY
Sex and heredity of the retinoblastoma patients
are shown in Table 2. Forty nine of the 350
hereditary retinoblastoma patients (14%) had
the unilateral form; 320 of the 635 unilateral
tumours were sited in the right eye and 296 in
the left eye; in 19 unilateral cases the location
of the tumour was unknown. The retinoblast-
oma subcohort 1945–94 has nearly the same
composition as the total cohort (data not
shown).
INCIDENCE BY SEX
In the period 1862–1995, no significant diVer-
ence was found in incidence for retinoblastoma
between males and females in the retinoblast-
oma subgroups (sporadic hereditary, familial
hereditary, and non-hereditary). Furthermore,
our investigation did not reveal any significant
diVerence between the male/female ratio in
various retinoblastoma subgroups and the
Dutch population. Moreover, in the subcohort
1945–94 no significant diVerence in male/
female ratio was found between the diVerent
retinoblastoma subgroups, or compared with
the Dutch population (data no shown).
TIME TRENDS IN INCIDENCE
Figure 1 shows the number of retinoblastoma
patients per 100 000 life births in 5 year
cohorts in the Netherlands. The incidence of
retinoblastoma increased significantly from
1862 to 1945. After 1945 there was no
evidence of an increase in the total incidence of
retinoblastoma, nor was there any significant
change in incidence in the retinoblastoma sub-
groups (sporadic hereditary, familial heredi-
tary, and non-hereditary retinoblastoma; data
not shown). The average incidence of retino-
blastoma after 1945 was 1:17 000 (95% CI;
1:15 500–1:18 500) (5.8 per 100 000) live
births (range 13 000–25 000).
Table 1 Incidence figures of retinoblastoma cited in the literature
Population
Time
period
No of
cases Incidence* Reference
Africa
Bantu, South Africa 1955–75 80 1:10 000 Freedman and Goldberg, 19762
Malawi 1975 20 1:10 000 BenEzra and Chirambo, 19763
America
USA 1969–71 59 1:18 000 Devesa, 19754
Michigan, USA ? 49 1:20 000 Falls and Neel, 19515
Ohio, USA ? 126 1:24 000 Macklin, 19616
USA 1974–6 70 1:18 000 Pendergrass and Davis, 19807
Asia
Hokkaido, Japan 1945–57 69 1:24 000 Matsunaga and Ogyu, 19598
Nagasaki, Japan 1965–86 34 1:16 000 Takano et al, 19919
Australia, New Zealand
Australia 1956–76 80 1:17 000 O’Day et al, 197710
New Zealand 1948–77 100 1:18 000 Suckling et al, 198211
Europe
Denmark 1928–57 118 1:19 000 Bech and Jensen, 196112
Finland 1950–64 ? 1:16 000 Tarkkanen and Tuovinen, 197113
France 1951–60 295 1:28 000 Briard-Guillemot et al, 197414
Germany 1934–51 48 1:29 000 Vogel, 19791
Great Britain 1962–80 431 1:23 000 Sanders et al, 198815
The Netherlands 1927–9 ? 1:34 000 Hemmes, 193116
The Netherlands 1945–70 486 1:16 000 DerKinderen et al, 199017
Northern Ireland 1938–56 23 1:27 000 Stevenson and Martin, 195718
Norway 1950–73 75 1:17 000 Hørven, 197319
Sweden 1958–71 88 1:18 000 Kock and Naeser, 197320
Middle East
Riyadh, Saudi Arabia 1982–6 22 1:12 000 Al-Idrissi et al, 199121
*Incidence in number of retinoblastoma patients per live births.
Table 2 Sex and heredity of patients in the National
Retinoblastoma Register of the Netherlands from 1862 to
1995
Group Male (%) Female (%) Total
Non-hereditary 318 (54.3) 268 (45.7) 586
Sporadic hereditary 130 (52.2) 119 (47.8) 249*
Familial hereditary 47 (46.5) 54 (53.5) 101†
Unknown 8 11 19
Total 503 (52.7) 452 (47.3) 955
*Including 29 unilateral patients.
†Including 20 unilateral patients.
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INCIDENCE PER MONTH
The distribution of the retinoblastoma sub-
groups does not show significant diVerences
over the 12 months of the year in comparison
with the Dutch population. There appears to
be a slight, but not significant excess of retino-
blastoma aVected newborns fromDecember to
May (data not shown).
SURVIVAL
In all, 287 of the 955 patients born between
1862 and 1995 had died; 640 patients were still
alive and 28 patients could not traced for
follow up. Five hundred and thirty eight
patients of the subcohort 1945–94 were still
alive; 99 patients had died and eight patients
could not be traced for follow up. Cumulative
survival at 5 and 35 years of age for the diVer-
ent retinoblastoma subgroups is shown in
Table 3. There was a significant diVerence in
cumulative survival between hereditary and
non-hereditary retinoblastoma (p<0.005). The
diVerence in survival between sporadic heredi-
tary and familial hereditary survival was not
significant. The diVerence in survival between
male and female retinoblastoma patients was
also not statistically significant.
The survival at 5 years (p<0.01) and 35
years (p<0.01) of age was significantly better
for patients born after 1945 than for patients
born before 1945. SMRs for the period 1898–
1995 are given in Table 4. No trend in the
SMR could be found for the total group of
patients. However, for the hereditary patients
the SMR increased significantly (p=0.007),
while for the non-hereditary patients a signi-
ficant decrease trend was found (p=0.017).
Discussion
HEREDITY
The percentage of hereditary and non-
hereditary retinoblastoma (61.4% and 36.6%,
respectively) was similar to the percentage
published by Vogel.1 In addition, he found that
10%–12% of the unilateral sporadic cases were
in fact new germline mutants; we found a
nearly similar percentage of 14.0.
INCIDENCE BY SEX
Several studies showed no sex diVerences in
the incidence of retinoblastoma.5 11 35 Nau-
mova and Sapienza26 made an extensive
compilation of the literature regarding sex and
laterality of proved sporadic cases and found a
significant overrepresentation of males among
bilateral sporadic cases. For unilateral retino-
blastoma they could not find such a diVerence.
We could not confirm their first mentioned
findings.
TIME TRENDS IN INCIDENCE
As discussed by Vogel1 studies covering more
recent periods tend to give higher values of
incidence of retinoblastoma. The most obvious
explanation is a more complete ascertainment
in the more recent studies. This can also
explain the increasing incidence we found in
the period 1862–1944. It seems that especially
in the period 1862–1900 the tumour was often
not recognised and/or registered. Vogel1 did
not exclude that there has been a true increase
in incidence of retinoblastoma. However, the
incidence in the period 1945–94 did not
change significantly in our study. Probably, in
this period the tumour was diagnosed correctly
and the register was really complete.
INCIDENCE PER MONTH
Earlier reports1 5 11 36 failed to show clustering
of sporadic hereditary or non-hereditary
retinoblastoma in specific months. Our data
revealed fluctuations to some extent by month
of birth, but this was not statistically signifi-
cant.
SURVIVAL
In 1809, Wardrop25 advocated enucleation of a
retinoblastoma containing eye as a lifesaving
measure. It is the general opinion that early
enucleation contributed to a better survival.24
However, new treatment modalities (irradia-
Figure 1 Incidence of retinoblastoma in the Netherlands in 5 year cohorts from 1862 to
1994. The incidence is expressed in number of retinoblastoma patients per 100 000 live
births in the Netherlands in the same period (irrespective of the moment of diagnosis).
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Table 3 Cumulative survival for the subcohorts of
retinoblastoma patients: 1945–94
Group No
Survival*
until age 5
Survival*
until age 35
Non-hereditary 395 91.8% 88.5%
Hereditary 242 87.2% 72.0%
Sporadic hereditary 164 87.4% 74.1%
Familial hereditary 78 86.8% 67.3%
Female 300 91.6% 84.3%
Male 337 88.7% 80.3%
All 637 90.1% 82.2%
*Survival per number of liveborn retinoblastoma patients.
Table 4 Standardised mortality ratio (SMR) for
retinoblastoma patients
Cohort
All RB Hereditary Non-hereditary
SMR
(95% CI)
SMR
(95% CI)
SMR
(95% CI)
1898–1907 1.4 (0.7–2.6) — 1.9 (1.0–3.7)
1908–17 2.7 (1.7–4.3) 2.9 (1.1–7.4) 2.7 (1.6–4.8)
1918–27 3.2 (2.2–4.7) 3.6 (2.1–6.2) 2.9 (1.7–5.0)
1928–37 3.3 (2.2–4.9) 4.5 (2.5–8.2) 2.4 (1.4–4.3)
1939–47 2.2 (1.4–3.3) 2.6 (1.3–5.0) 1.8 (1.0–3.2)
1948–57 2.6 (1.8–3.7) 3.3 (1.9–6.0) 2.1 (1.3–3.5)
1958–67 3.0 (2.1–4.3) 5.0 (3.0–8.0) 2.1 (1.3–3.5)
1968–77 2.6 (1.8–3.7) 5.5 (3.4–8.9) 1.6 (1.0–2.8)
1978–87 2.8 (2.0–3.9) 5.7 (3.6–9.0) 1.7 (1.0–2.9)
1988–95 3.1 (2.1–4.7) 9.0 (5.5–14.4) 1.0 (0.5–2.3)
RB = retinoblastoma.
95% CI = 95% confidence interval.
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tion or coagulation) were developed to save life
and preserve vision. Bishop and Madsen37
reported an increase in the survival of retino-
blastoma of 5% in 1869 to 81% in 1967. This
study also showed an increasing survival. It
should be stressed also that from 1900 the sur-
vival in the general population34 increased dra-
matically. Taking this into account, it is clear
from the trend analysis of the SMR that
survival for the hereditary group could not fol-
low the improvement in the general popula-
tion.
The risk of death is significantly higher for a
retinoblastoma patient than for an average
member of the Dutch population, as all SMRs
are larger than 1. In other words, the improved
diagnostic technique and improved retino-
blastoma treatment did not result in the same
length of survival for the general Dutch popu-
lation and patients with hereditary retinoblast-
oma, in particular. Mortality increased signifi-
cantly compared with the mortality of the
general population (p=0.007). In contrast,
there was a significantly decreased ‘extra
mortality’ of the non-hereditary patients
(p=0.017). These findings can probably be
explained by the hereditary retinoblastoma
gene disorder. Hereditary retinoblastoma pa-
tients are vulnerable for second primary
tumours and pineoblastomas.30 Furthermore,
treatment of hereditary (bilateral) retinoblast-
oma patients is more often irradiation than that
of non-hereditary patients, because non-
hereditary patients are mostly enucleated. Der-
Kinderen et al 38 have shown that irradiation
therapy is an extra risk factor for second
primary tumours in hereditary retinoblastoma
patients. This will lead to death in many cases.
On the other hand no second primary tumours
were induced by irradiation of non-hereditary
retinoblastoma patients39; consequently, non-
hereditary retinoblastoma patients will be
cured and survival will be improved.
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